Rizatriptan Disintegrating Oral Tablet [Maxalt]
RxNorm 828535
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 828535 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: rizatriptan Disintegrating Oral Tablet [Maxalt].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDFPrescribable
Semantic Branded Drug Form (SBDF):
Rizatriptan Disintegrating Oral Tablet [Maxalt]
(Atom ID: 6346632)
Patient Education
Rizatriptan
Rizatriptan is used to treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Rizatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Rizatriptan does not prevent migraine attacks or reduce the number of headaches you have.
[Learn More]
* Please review the disclaimer below.